[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fa4cwPNTMdIKv_pTvXIs80ymecnHOtGlZELxhsIXM73s":8,"$ftMvUlO6FgvebdN89SjZI0CczPjychH_BIeZOrMWDGvg":55,"$fe1T4f2GeJcvVPdDyIJstv1c7QUXkAM9egyrYvymdrXc":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},68902,867263,[],"https://ystcdn.venuertc.com/medical/ystApp/0YbWrtsGnIVSTzEaDbtlD7CaJRSwuqG9.png","李会敏","临清市人民医院","老年病内科","住院医师",384,0,"紫杉醇脂质体与卡铂等药物：子宫内膜肿瘤 IV期治疗用药实用指南 🌸","","https://ystcdn.venuertc.com/venue/AI/731b400a-3412-4abf-b5dd-184b228c1558.jpg","\u003Cdiv class=\"material-container\">\n  \u003Ch1 id=\"material_title\" class=\"material-title\">紫杉醇脂质体与卡铂等药物：子宫内膜肿瘤 IV期治疗用药实用指南 \u003C/h1>\n  \n  \u003Cdiv class=\"material-intro\">\n    \u003Cp>\n      说到紫杉醇脂质体和卡铂这两种药物，相信不少身边的朋友都听说过，它们常见于妇科领域的化疗方案中，属于抗肿瘤类药物。服用这类药物，细节非常关键。本文将为大家梳理7个点，帮你真正搞清楚这些药物怎么用、用时注意什么、如何减少风险，更加放心地配合治疗。\n    \u003C/p>\n  \u003C/div>\n  \n  \u003C!-- 01 剂型与成分特性 -->\n  \u003Csection class=\"material-section\">\n    \u003Ch2 class=\"material-subtitle material-bg1\">💊 剂型与成分特性\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>\n        紫杉醇脂质体（Paclitaxel Liposome）是一种注射用抗肿瘤药，利用脂质体包裹达到靶向输送降低副作用；规格一般为30mg/瓶或60mg/瓶粉剂。卡铂（Carboplatin）同样为静脉注射型抗肿瘤药物，规格多为50mg/瓶、150mg/瓶或450mg/瓶。两者因给药途径为注射，在配药及输注过程中有严格要求，严禁口服和自行调整剂量。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 02 作用机制简明介绍 -->\n  \u003Csection class=\"material-section\">\n    \u003Ch2 class=\"material-subtitle material-bg2\">🔬 作用机制简明介绍\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>\n        紫杉醇脂质体属于微管蛋白抑制剂，主要通过干扰细胞分裂过程，阻断细胞有丝分裂。脂质体包裹有助于减轻周边神经及肾毒性。卡铂为铂类化合物，作用机理是结合细胞DNA，阻止DNA复制，最终导致细胞死亡。两种药联用能在杀灭异常增殖细胞方面互补，提升疗效 \u003Cspan class=\"material-cite\">(McGuire et al., 1996; Calvert, 2001)\u003C/span>。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 03 用法用量及应用流程 -->\n  \u003Csection class=\"material-section\">\n    \u003Ch2 class=\"material-subtitle material-bg3\">⏱ 服药时间与用法用量\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>\n        正确做法：这两种药都属于静脉滴注药物，严禁口服。用药周期通常为每3-4周一疗程。紫杉醇脂质体先予滴注，再用卡铂。输液前半小时推荐给予抗过敏药，防止超敏反应。每次用量根据体表面积和肾功能调整，不能私自更改。\n      \u003C/p>\n      \u003Cul>\n        \u003Cli>输液时间：紫杉醇脂质体建议超过1小时，卡铂一般30分钟至1小时。\u003C/li>\n        \u003Cli>特殊情况：出现发热、寒战、皮疹、呼吸不适，必须立即停药并告知医护人员。\u003C/li>\n      \u003C/ul>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 04 药物相互作用细节 -->\n  \u003Csection class=\"material-section\">\n    \u003Ch2 class=\"material-subtitle material-bg4\">⚠️ 药物相互作用说明\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>\n        紫杉醇脂质体和卡铂都可能与多种药物相互影响。典型需注意如下：\n      \u003C/p>\n      \u003Cul>\n        \u003Cli>避免同时应用其他肝酶抑制剂，例如酮康唑、红霉素，会影响紫杉醇代谢。\u003C/li>\n        \u003Cli>卡铂和铱类、顺铂等金属类抗肿瘤药物联用时，肾毒性风险上升。\u003C/li>\n        \u003Cli>与利福平、苯妥英、华法林同用时需密切监测血象变化和出血风险。\u003C/li>\n        \u003Cli>可与生理盐水或葡萄糖溶液配伍，避免与氯化钙等高渗溶液混用。\u003C/li>\n      \u003C/ul>\n      \u003Cp>药物间隔顺序很重要，通常需要紫杉醇在卡铂前滴注，逆序可能降低疗效。\u003C/p>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 05 特殊人群使用调整 -->\n  \u003Csection class=\"material-section\">\n    \u003Ch2 class=\"material-subtitle material-bg5\">👵 特殊人群用药调整与案例\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>\n        老年患者、肾功能减退者、既往有过敏史者，用药需特别调整。例如：\n      \u003C/p>\n      \u003Cul>\n        \u003Cli>\n          一位70岁女性在使用卡铂时，根据肾功能检查调整剂量，有效减少了骨髓抑制风险。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        孕妇和哺乳期女性需避免使用，两药物可影响胎儿发育及乳汁分泌。儿童患者的安全性和疗效研究有限，需严格按医生指导。\n      \u003C/p>\n      \u003Cp>\n        肝功能异常的患者，紫杉醇脂质体剂量需要个体化调整，以免加重肝损伤\u003Cspan class=\"material-cite\">(Markman, 2000)\u003C/span>。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 06 常见不良反应及处理 -->\n  \u003Csection class=\"material-section\">\n    \u003Ch2 class=\"material-subtitle material-bg6\">🤒 常见不良反应与应对措施\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>\n        紫杉醇脂质体—卡铂方案容易引发以下状况👇：\n      \u003C/p>\n      \u003Cul>\n        \u003Cli>\n          1度骨髓抑制：表现为白细胞、中性粒细胞或血小板降低，建议过程中定期血常规检测，严重时暂停或减少剂量。\n        \u003C/li>\n        \u003Cli>\n          轻中度脱发、乏力：用药期间为常见副作用，大多用药后恢复。\n        \u003C/li>\n        \u003Cli>\n          消化系统反应：恶心、呕吐、口腔溃疡较多见，用药前可根据医嘱服用止吐药。\n        \u003C/li>\n        \u003Cli>\n          过敏反应：部分患者可出现皮疹、发热、喘鸣等。如果有急性过敏，立即停止滴注并予急救处理。\n        \u003C/li>\n        \u003Cli>\n          肾功能受损的高风险患者，卡铂剂量需适当下调，监测尿量、电解质和肌酐。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        临床研究数据显示，紫杉醇脂质体联合卡铂的骨髓抑制风险好于常规溶剂型紫杉醇\u003Cspan class=\"material-cite\">(Guastalla et al., 2001)\u003C/span>。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 07 储存方法与用药流程 -->\n  \u003Csection class=\"material-section\">\n    \u003Ch2 class=\"material-subtitle material-bg7\">📦 储存方法与安全用药流程\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>\n        正确做法：\n      \u003C/p>\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>储存：\u003C/strong>注射用粉剂应存于密封、阴凉干燥处，温度建议不高于25℃。切忌冷冻、避免强光直射，配制好的溶液建议48小时内用完。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>过期药品：\u003C/strong>如变色、絮状沉淀或超过标注有效期，严禁再用，应及时交医院药房集中处理。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>用药前检查：\u003C/strong>包括药品外观、药瓶完整性、消毒处理。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>静脉输注：\u003C/strong>须由专业护士操作。用药时间掌控很重要，太快易致反应。\n        \u003C/li>\n      \u003C/ul>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 08 漏服与超量补救 -->\n  \u003Csection class=\"material-section\">\n    \u003Ch2 class=\"material-subtitle material-bg8\">⛑ 漏服与过量应对方法\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>\n        由于紫杉醇脂质体和卡铂均为院内用药，漏服可能性很小。如果因特殊情况推迟输注，需医生重新制定方案，不可“补打”以纠正。超量使用时，最典型表现为骨髓抑制加重、肾肝损伤，此时应立即停止用药并积极支持治疗。\n      \u003C/p>\n      \u003Cp>\n        日常需记下每次用药日期及反应，方便医护追踪和调整。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 09 其他辅助药物简介（酌情） -->\n  \u003Csection class=\"material-section\">\n    \u003Ch2 class=\"material-subtitle material-bg9\">💡 辅助药物及综合用药安全\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>\n        在静脉化疗期间，辅助药物的使用也很常见。例如，注射用升白细胞药物、口服止吐药（如昂丹司琼）、抗过敏药（如地塞米松）常被临时联合，以减少不良反应。每种药都需遵循医嘱，不得替换或随意更改。\n      \u003C/p>\n      \u003Cul>\n        \u003Cli>\n          一例患者在化疗后辅助使用升白针，有效缩短了白细胞恢复周期。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        合理搭配辅助药物，可显著提升整体耐受性，减少骨髓抑制及消化道反应的发生率。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 10 总结与实践建议 -->\n  \u003Csection class=\"material-section material-bg10\">\n    \u003Ch2 class=\"material-subtitle\">🏅 实用小结与安全提醒\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>\n        紫杉醇脂质体和卡铂作为静脉注射抗肿瘤药，对操作和时间要求严格。重点要记住3点：第一，必须全程按医嘱规范输注，不能自调剂量；第二，各类药物、辅助药联用时要清楚先后次序；第三，坚持每次检测，及时应对不良反应，对于特殊人群如老年、肝肾功能异常患者，更要个体化调整。遇到新症状或异常，及时向医护反映，让专业人员及时介入，是安全用药最有效的保障。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 参考文献 -->\n  \u003Csection class=\"material-section material-bg11\">\n    \u003Ch2 class=\"material-subtitle\">📚 参考文献\u003C/h2>\n    \u003Cul class=\"material-list\">\n      \u003Cli>\n        McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., ... & Childers, J. M. (1996). Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. \u003Cem>New England Journal of Medicine, 334\u003C/em>(1), 1-6.\n      \u003C/li>\n      \u003Cli>\n        Calvert, A. (2001). Carboplatin–Twenty-five years of clinical studies. \u003Cem>Annals of Oncology, 13\u003C/em>(3), 265-268.\n      \u003C/li>\n      \u003Cli>\n        Guastalla, J. P., Dieras, V., Roché, H., et al. (2001). The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. \u003Cem>British Journal of Cancer, 84\u003C/em>(23), 1387–1394.\n      \u003C/li>\n      \u003Cli>\n        Markman, M. (2000). Safety profile of the platinum analogues. \u003Cem>Seminars in Oncology, 27\u003C/em>(3 suppl 7), 24-27.\n      \u003C/li>\n    \u003C/ul>\n  \u003C/section>\n\u003C/div>\n\n\u003Cstyle>\n.material-container {\n  font-family: \"Helvetica Neue\", Arial, \"PingFang SC\", \"Microsoft YaHei\", sans-serif;\n  background: #fbfc;\n  max-width: 800px;\n  margin: 0 auto;\n  padding: 40px 24px 40px 24px;\n  border-radius: 16px;\n  box-shadow: 0 3px 24px rgba(180,180,190,0.09);\n}\n.material-title {\n  font-size: 2.3em;\n  color: #2f466e;\n  letter-spacing: 1px;\n  line-height: 1.2;\n  margin-bottom: 36px;\n  margin-top: 0;\n  text-align: left;\n}\n.material-intro {\n  font-size: 1.18em;\n  padding: 18px 16px;\n  background: #f3f6fc;\n  border-left: 5px solid #97a9d0;\n  color: #34495e;\n  border-radius: 7px;\n  margin-bottom: 36px;\n}\n.material-section {\n  margin: 32px 0 28px 0;\n  padding: 0 0 6px 0;\n  border-radius: 9px;\n  background: #fff;\n  box-shadow: 0 1px 4px rgba(180,180,190,0.04);\n}\n.material-content {\n  font-size: 1.06em;\n  color: #383e49;\n  padding: 18px 20px 13px 22px;\n  line-height: 1.85em;\n}\n.material-content ul {\n  margin: 7px 0 7px 18px;\n  padding-left: 15px;\n  color: #2f466e;\n  font-size: 1em;\n}\n.material-content li {\n  margin-bottom: 7px;\n  line-height: 1.5em;\n  list-style: disc;\n}\n.material-subtitle {\n  font-size: 1.25em;\n  font-weight: 600;\n  padding: 13px 20px;\n  margin: 0;\n  border-radius: 7px 7px 0 0;\n  color: #22408a;\n  letter-spacing: 0.5px;\n}\n.material-bg1 {\n  background: linear-gradient(90deg,#e0eafc 1%,#f8f8fa 100%);\n}\n.material-bg2 {\n  background: linear-gradient(90deg,#e5f7fa 1%,#f7f8fa 100%);\n}\n.material-bg3 {\n  background: linear-gradient(90deg,#dbe7f4 1%,#f7fafd 100%);\n}\n.material-bg4 {\n  background: linear-gradient(90deg,#f4ecef 1%,#f3f8fa 100%);\n}\n.material-bg5 {\n  background: linear-gradient(90deg,#eef5ec 1%,#f8faf5 100%);\n}\n.material-bg6 {\n  background: linear-gradient(90deg,#f7f5ec 1%,#f9faf4 100%);\n}\n.material-bg7 {\n  background: linear-gradient(90deg,#e7eeec 1%,#f7faf5 100%);\n}\n.material-bg8 {\n  background: linear-gradient(90deg,#fbeefd 1%,#faf8f5 100%);\n}\n.material-bg9 {\n  background: linear-gradient(90deg,#ecfafd 1%,#f8fbfa 100%);\n}\n.material-bg10 {\n  background: linear-gradient(90deg,#f8f5e6 1%,#fafafd 100%);\n}\n.material-bg11 {\n  background: linear-gradient(90deg,#ecf0f8 1%,#f8fbfe 100%);\n}\n.material-list {\n  margin: 10px 0 10px 32px;\n  color: #49596d;\n  font-size: 1em;\n  line-height: 1.75em;\n  list-style: decimal;\n}\n.material-cite {\n  font-size: 0.96em;\n  color: #9baaab;\n  margin-left: 4px;\n}\n@media (max-width: 540px) {\n  .material-container {\n    max-width: 97%;\n    padding: 12px 2px 15px 2px;\n  }\n  .material-title {\n    font-size: 1.25em;\n    margin-bottom: 20px;\n    margin-top: 8px;\n  }\n  .material-section {\n    margin: 15px 0 13px 0;\n  }\n  .material-content {\n    padding: 9px 5px 8px 10px;\n  }\n  .material-subtitle {\n    padding: 8px 8px;\n    font-size: 1em;\n  }\n}\n\u003C/style>","\u003Cdiv class=\"material-container\">\n  \u003Ch1 id=\"material_title\" class=\"material-title\">紫杉醇脂质体与卡铂等药物：子宫内膜肿",519,"2025-10-29 00:48:43","紫杉醇脂质体, 卡铂, 子宫内膜肿瘤, 化疗药物, 不良反应, 用法用量, 药物相互作用, 特殊人群","本文详细介绍紫杉醇脂质体和卡铂在子宫内膜肿瘤IV期的治疗中应用，强调用法注意、相互作用及不良反应处理，为患者提供实用建议和指导。","2025-11-16 06:30:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]